Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Bergapten, isolated from Bergamot, inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 24/February/2017, 11.27 pm

Combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: 15-deoxy-delta(12,14)-prostaglandin J2 (PGJ2) decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 24/January/2017, 11.01 pm
February 24, 2017
Natural product/vitamin-based Combination therapy for PTEN-deficient cancer: Combination of Schisandrin B, Cholecalciferol and ATRA decreases the expression of CHD1, increases the expression of a number of tumor suppressor genes, inhibits pro-survival TNF-NF-kB gene network, and suppresses tumorigenesis of PTEN-deficient cancer, 24/February/2017, 11.43 pm
February 24, 2017
Show all

Introduction:What they say:

A recent study from Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA shows that “Deubiquitination and Stabilization of PD-L1 by CSN5.” This study was published in the 12 December 2016 issue of Cancer cell (one of the best journals in Cancer Science with an impact factor of 23.523) by Prof Mien-Chie Hung, Lim SO and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Bergapten, isolated from Bergamot, inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene


What is known?

It has recently been shown that blocking cell surface receptor PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year recently.


From Research Findings to Therapeutic opportunity

Bergapten, by increasing the expression of its target gene, it may  ubiquitinate and destabilize PD-L1 (fig. 1). Thereby, it may: (i) diminish PD-L1 expression in cancer cells; (ii) inhibit inflammatory TNFα signaling; (iii) decrease the number of tumor-infiltrating lymphocytes and macrophages; (iv) increase T-cell anti-tumor immunity; (v) decrease tumor burden; and (vi) increase survival of patients with breast cancer (fig. 1).  

Bergapten inhibits PDL1 expression

Figure 1. Mechanistic insight into how Bergapten enhances the efficacy of cancer immunotherapy. Bergapten, by decreasing the expression of PD-L1 in cancer cells, it augments T-cell mediated anti-tumor immunity

Thus, pharmacological formulations encompassing “Bergapten or its analogues or Bergapten in combination with other drugs may be used to (i) inhibit the progression of tumors; and (ii) enhance the efficacy of Cancer immunotherapy.price-50

[easy_payment currency=”USD”]


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $50

Undisclosed mechanistic information: How Bergapten suppresses the expression of PD-L1 and augments anti-tumor immunity

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References

Citation: Boominathan, L., Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Bergapten, isolated from Bergamot, inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 24/February/2017, 11.29 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.